{"id":39849,"date":"2017-07-14T07:00:17","date_gmt":"2017-07-14T11:00:17","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=39849"},"modified":"2017-07-14T07:00:17","modified_gmt":"2017-07-14T11:00:17","slug":"elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849","title":{"rendered":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment"},"content":{"rendered":"<p>Shares of <strong>Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)<\/strong> traded higher in Monday\u2019s trading session as investors reacted to topline results from a pivotal bioequivalence fed study of SequestOx.<\/p>\n<h2><strong>Topline SequestOx Results <\/strong><\/h2>\n<p>Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) is a specialty pharmaceutical company focused on the development of proprietary pharmacological abuse deterrent opioid products. The pharmaceutical company has eight commercial products on sale, in addition to approved products pending manufacturing. The company also owns generic and OTC products licensed to TAGI Pharma and Valeant Pharmaceuticals International.<\/p>\n<p>Topline results for SequestOx affirm the company\u2019s proprietary abuse deterrent technology. SequestOx is Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) investigational product for the management of moderate to severe acute pain. The bioequivalence study carried on the opioid was a pivotal open-label, randomized clinical study evaluating the bioavailability of the modified formulation to a comparator under fed conditions.<\/p>\n<p>Compared to Roxicodone the candidate drug achieved a Tmax of 4.6hr with a range of 0.5 hr. to 12hr. Elite will not proceed with the rest of clinical trials on the drug, pending FDA clarity on the next steps needed for the release of SequestOx.<\/p>\n<p>\u201cWe were hoping for better and more decisive results for the reformulated immediate release version of SequestOx. We remain positive with respect to Elite\u2019s abuse-deterrent and generic pipeline. We will see the results of our hard work over the next six to twelve months,\u201d <a href=\"https:\/\/finance.yahoo.com\/news\/elite-pharmaceuticals-reports-topline-results-164818587.html\" target=\"_blank\" rel=\"noopener\">said<\/a> CEO, Nasrat Hakim.<\/p>\n<h2><strong>ANDA Fillings <\/strong><\/h2>\n<p>Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) is on target on its pipeline objectives for 2017 after the top line SequestOx results. The Company plans to file one ANDA application this quarter and an additional two in the fourth quarter.<\/p>\n<p>ANDA filling already made, target markets where branded products generic equivalents generate annual sales of $4 billion according to IMS health data. The company is in the process of making an application for a generic version of OxyContin that generated sales of $2.5 billion in 2015.<\/p>\n<p>SequestOx topline results build on positive results for an undisclosed product that Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) is developing in partnership with SunGen Pharma. The generic product under development is bioequivalent to a branded product in both fasted and fed studies. If approved the drug will expand the company\u2019s footprint into a generic market worth $600 a million in revenues a year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) traded higher in Monday\u2019s trading session as investors reacted to topline results from a pivotal bioequivalence fed study of [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":39856,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12766,12765,101,12422,12767],"stock_ticker":[],"class_list":["post-39849","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-elite-pharmaceuticals-inc","tag-elite-pharmaceuticals-inc-otcmktseltp","tag-eltp","tag-otcmkts","tag-otcmktseltp","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) traded higher in Monday\u2019s trading session as investors reacted to topline results from a pivotal bioequivalence fed study of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-07-14T11:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"308\" \/>\n\t<meta property=\"og:image:height\" content=\"164\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment\",\"datePublished\":\"2017-07-14T11:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\"},\"wordCount\":393,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg\",\"keywords\":[\"Elite Pharmaceuticals Inc.\",\"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)\",\"ELTP\",\"OTCMKTS\",\"OTCMKTS:ELTP\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\",\"name\":\"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg\",\"datePublished\":\"2017-07-14T11:00:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg\",\"width\":308,\"height\":164},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849","og_locale":"en_US","og_type":"article","og_title":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR","og_description":"Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) traded higher in Monday\u2019s trading session as investors reacted to topline results from a pivotal bioequivalence fed study of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-07-14T11:00:17+00:00","og_image":[{"width":308,"height":164,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg","type":"image\/jpeg"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment","datePublished":"2017-07-14T11:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849"},"wordCount":393,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg","keywords":["Elite Pharmaceuticals Inc.","Elite Pharmaceuticals Inc. (OTCMKTS:ELTP)","ELTP","OTCMKTS","OTCMKTS:ELTP"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849","url":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849","name":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg","datePublished":"2017-07-14T11:00:17+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/07\/39855-images__4_.jpeg","width":308,"height":164},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/elite-pharmaceuticals-inc-otcmktseltp-rallies-on-topline-fed-study-results-for-pain-management-treatment-39849#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Rallies On Topline Fed Study Results For Pain Management Treatment"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=39849"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/39849\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/39856"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=39849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=39849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=39849"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=39849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}